New research article

#Bedaquiline resistance in patients with Xpert MTB/RIF Ultra-tested #rifampicin resistant #tuberculosis in the Western Cape, South Africa: a prospective study

www.thelancet.com/journals/lan...

#IDSky #ClinMicro #TBSky #TB #AMR #OpenAccess #OA

ACTnet (Australasian Clinical TB Network) Tuberculosis (TB) remains a leading infectious cause of death worldwide, and an important cause of morbidity among migrants arriving in Australia and New Zealand. The Australasian Clinical Tuberculosi...

Hey #TBsky,

@actnet.bsky.social has launched a YouTube page with recent journal clubs and webinars on all things #tuberculosis

Catch Dr Tasnim Hasan's take on the emerging data around #bedaquiline resistant TB treatment outcomes.

youtube.com/@actnet_tb?s...

#IDsky

Read the Journal of #Infection for the study assessing the effectiveness of #bedaquiline, #pretomanid and #linezolid regimens with varying doses and duration of #linezolid at the end of 48 weeks post treatment among drug resistant #tuberculosis patients 👉 www.journalofinfecti...

Molecular structure of tuberculosis efflux pump reveals how bacteria resist key antibiotic Tuberculosis is the world's leading infectious cause of death, killing more than one million people each year. When the antibiotic bedaquiline was introduced in 2012, it was the first new…

Molecular structure of #tuberculosis #efflux pump reveals how #bacteria resist key #antibiotic ...

| #bedaquiline | #drugresistance | #Mycobacterium | #mycobactin | #pathogen | Via @sciencex.bsky.social‬

#medsky #bedaquiline #infectiousdisease #episky #publichealth #drugprices #tuberculosis #TB #stopTB #goodnews #happynews

Union list of critical medicines | European Medicines Agency (EMA) The Union list of critical medicines supports the joint work of the European Medicines Agency (EMA), the European Commission (EC) and the Heads of Medicines Agencies (HMA) in preventing issues with th...

The updated version of the European Union List of Critical Medicines is out. 💊📃 www.ema.europa.eu/en/human-reg...
Meanwhile, in #Canada, medicines listed as critical in the EU (and #EssentialMedicines by the WHO) like #bedaquiline and #albendazole still aren't formally available...

#Bedaquiline access update: This week, Indian patent office rejected Johnson&Johnson's patent application for long-acting injectable bedaquiline, primarily developed for #TB preventive therapy, opening the door for generics —hopefully soon for prevention too. Thanks to #TBactivism #IDSky #TBSky 🥳🥳🥳

Intranasal Administration of Bedaquiline-Loaded Fucosylated Liposomes Provides Anti-Tubercular Activity while Reducing the Potential for Systemic Side Effects Liposomal formulations of antibiotics for inhalation offer the potential for the delivery of high drug doses, controlled drug release kinetics in the lung, and an excellent safety profile. In this study, we evaluated the in vivo performance of a liposomal formulation for the poorly soluble, antituberculosis agent, bedaquiline. Bedaquiline was encapsulated within monodisperse liposomes of ∼70 nm at a relatively high drug concentration (∼3.6 mg/mL). Formulations with or without fucose residues, which bind to C-type lectin receptors and mediate a preferential binding to macrophage mannose receptor, were prepared, and efficacy was assessed in an in vivo C3HeB/FeJ mouse model of tuberculosis infection (H37Rv strain). Seven intranasal instillations of 5 mg/kg bedaquiline formulations administered every second day resulted in a significant reduction in lung burden (∼0.4–0.6 Δlog10 CFU), although no differences between fucosylated and nonfucosylated formulations were observed. A pharmacokinetic study in healthy, noninfected Balb/c mice demonstrated that intranasal administration of a single dose of 2.5 mg/kg bedaquiline liposomal formulation (fucosylated) improved the lung bioavailability 6-fold compared to intravenous administration of the same formulation at the same dose. Importantly, intranasal administration reduced systemic concentrations of the primary metabolite, N-desmethyl-bedaquiline (M2), compared with both intravenous and oral administration. This is a clinically relevant finding as the M2 metabolite is associated with a higher risk of QT-prolongation in predisposed patients. The results clearly demonstrate that a bedaquiline liposomal inhalation suspension may show enhanced antitubercular activity in the lung while reducing systemic side effects, thus meriting further nonclinical investigation.

A new #nanomedicine in the fight against #tuberculosis? Scientists from the ANTI-TB consortium discovered that inhaled liposomal #bedaquiline, has the potential to improve the pharmacokinetic profile of the drug compared to a conventional oral form.
pubs.acs.org/doi/10.1021/...

Bedaquiline: what might the future hold? Tuberculosis drug development has stagnated for decades, so the recent availability of bedaquiline is welcome. Bedaquiline-containing regimens, now the first-line therapy recommended by WHO, have tran...

New personal view article in The Lancet Microbe

#Bedaquiline: what might the future hold?

www.thelancet.com/journals/lan...

#tuberculosis #TB #AMR #IDSky #MicroSky #OpenAccess #OA

New research article in The Lancet Microbe

MmpR5 protein truncation and #bedaquiline resistance in #Mycobacterium #tuberculosis isolates from South Africa: a genomic analysis

www.thelancet.com/journals/lan...

#AMR #TB #MicroSky #IDSky #OpenAccess #OA

Life-saving TB drug is now cheaper in South Africa, but not as cheap as it can be Johnson & Johnson has agreed to drop the price of bedaquiline to the South African government by more than 40%

#TB - Johnson & Johnson has agreed to drop the price of #bedaquiline to the South African government by more than 40%. www.groundup.org.za/article/life...